Brandon Rose, MD, MPH (@BRoseMDMPH) header
Brandon Rose, MD, MPH (@BRoseMDMPH) profile picture

UTSW Heme/Onc & Clinical Informatics Fellow 📊 Breast+GI+Sarcoma Oncology 🩺 #Rstats @thecodingdocs 💻 REDCap Coder 🧢 UMiami Med🌴 UCSB 🌊 Personal Opinions 🤠

Dallas, TX
Joined August 2021
Photo by Brandon Rose, MD, MPH (@BRoseMDMPH)Photo by Brandon Rose, MD, MPH (@BRoseMDMPH)Photo by Brandon Rose, MD, MPH (@BRoseMDMPH)Photo by Brandon Rose, MD, MPH (@BRoseMDMPH)Photo by Brandon Rose, MD, MPH (@BRoseMDMPH)Photo by Brandon Rose, MD, MPH (@BRoseMDMPH)Photo by Brandon Rose, MD, MPH (@BRoseMDMPH)Photo by Brandon Rose, MD, MPH (@BRoseMDMPH)Photo by Brandon Rose, MD, MPH (@BRoseMDMPH)Photo by Brandon Rose, MD, MPH (@BRoseMDMPH)
📣 Introducing {REDCapSync} and {RosyREDCap} @TheCodingDocs. Thanks for the @RConsortium and the @r_medicine conference for giving me the platform to share the culmination of years of experience in #rstats data pipelines. thecodingdocs.github.io/REDC…
5
4
53
4,901
Brandon Rose, MD, MPH retweeted
A great way to celebrate #LCAM26! 🎉 @FDA accelerated approval of #Neladalkib (Nelkarmi) for previously treated ALK+ advanced NSCLC marks another milestone in two decades of progress—and more hope for our patients. 🫁 ▶️ ALKOVE-1: ORR 49% post-alectinib; 32% after ≥2 ALK TKIs + platinum. 🎯 Durable responses: ≥12-month DOR in ~half of responders. 🧠 Promising CNS activity. ⚠️ Key AEs: transaminase elevations, GI effects, myalgias and edema. An important new salvage option for ALK+ lung cancer, including patients with CNS disease. #LCSM #ALK @ALKPositiveinc @ALKpositiveINT
🤖 Made with AI
21
43
2,301
The phase III SWOG S1418/NRG BR006 trial studies pembrolizumab after surgery for patients whose triple-negative breast cancer remained after preoperative chemotherapy. Lajos Pusztai, MD, DPhil, presents Dec. 9 at #SABCS26. Be part of what comes next: bit.ly/4zVrJXC
8
1
25
6,514
Brandon Rose, MD, MPH retweeted
Congratulations to medical oncologist Suzanne Cole, M.D., on receiving the UTSW Program Development Award for her efforts in developing and advancing our Community Oncology Program. Learn more about the award and check out Dr. Cole’s video: bit.ly/4kKVR2R.
5
16
635
Brandon Rose, MD, MPH retweeted
So I am definitely not advocating for this approach in all patients. The situation I mentioned in lobular breast cancer patients here is the one specific and only scenario I would do this in. The disease itself is quite different than ductal breast cancer and generally doesnt show up on CT.
1
1
233
Miss you guys! Congratulations!
🤖 Grateful to @SylvesterCancer for the recognition at the Sylvester Innovator 2026 Showcase! Our projects explored:
🔬 AI platforms for clinical decision-making in oncology - focused on EGFR Lung cancers.
📊 AI-assisted meta-analysis & network meta-analysis in collaboration with @Larvol to identify best trial match for specific subgroup population in Lung Cancer. AI is evolving rapidly, and its thoughtful integration into healthcare holds tremendous potential to advance precision medicine and evidence-based cancer care. Thankful to our mentors for constant support! @GlopesMd @dan_morgen @Latinamd @DionysiosWatson @DrSDNimer @EGFRResisters @jillfeldman4
6
514
Brandon Rose, MD, MPH retweeted
From TAILORx to OPTIMA: Evolving Evidence for Genomically Guided Chemotherapy in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Co-authored by @YAbdouMD and @DrLisaCarey. Read the full article. bit.ly/4yV3G9B #BreastCancer #bcsm
9
2
27
3,577
Brandon Rose, MD, MPH retweeted
🔥 After the oral presentation at #ESMO26, the concomitant publication of the final results from OptiTROP-Breast01 is online now 👉 Sacituzumab tirumotecan ⬆️ OS benefit vs chemotherapy in previously treated advanced TNBC 🔗shorturl.at/RxQE6
1
18
40
3,879
Brandon Rose, MD, MPH retweeted
There was a time when treating HER2+ breast cancer was relatively simple. That time is over. And that’s great news! Not long ago, we recommended TCHP for most patients with stage II–III disease, and THP (CLEOPATRA) for those with metastatic disease. Straightforward. Almost one-size-fits-all. Within just a few years, that simplicity is gone. And that’s progress. More opportunities to spare unnecessary toxicity, tailor treatments to patients’ preferences, and move beyond rigid algorithms. To be more doctors. In early-stage disease, options now range from de-escalated THP to intensified regimens such as DB11. In metastatic disease, T-DXd/P has achieved unprecedented PFS (>3 years in the 1L setting!), with novel maintenance strategies (palbociclib or tucatinib) potentially pushing the bar even higher. Meanwhile, biomarkers are finally coming of age, from imaging to tissue and plasma. What an era to be treating HER2+ breast cancer! But more options also mean more complexity. For oncologists, and especially for patients. More knowledge needed, more discussions, more decisions to make. How do we navigate this increasingly complex landscape and choose the right treatment for the right patient? We tried to offer some guidance in our new review recently published in @NatRevClinOncol. Read it here: nature.com/articles/s41571-0… @ValenzaCarmine
Check out this recent review 👉Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum. pubmed.ncbi.nlm.nih.gov/4285… @PTarantinoMD @ValenzaCarmine @elia_segui @nlinmd @curijoey @adawaksmd @stolaney1 #BreastCancer
31
4
113
10,296
We are now enrolling to the #CAPELA study! This is a new phase II multi-center open-label randomized study of #CAPecitabine in combination with #ELAcestrant versus capecitabine alone in advanced estrogen receptor-positive #BreastCancer. ​ To learn more about the #CAPELA study call 877-338-7425 or visit dana-farber.org/clinical-tri…​ PI: @KristinaFanucci #MetastaticBreastCancer #MBC #ClinicalTrial #BreastCancerResearch
1
7
18
839
At my first annual informatics meeting #AMIA2026! There are currently over 8,000 members of AMIA with ~30% representing students/trainees. These are the people implementing advancements in healthcare technology from health records to AI!
1
13
456
Brandon Rose, MD, MPH retweeted
Coming back from #SITC2026 with lots of new ideas! Exciting work on cancer vaccines, patient-derived models, and IL-12 delivery. Best of all the chance to catch up with friends and colleagues!
4
9
796
Brandon Rose, MD, MPH retweeted
Great news for our patients with head and neck cancers!!!! We got another FDA approval, this time for amivantamab in the second line setting and beyond. This is an area of SUCH need. A happy day indeed!!
🚨BREAKING🚨: The @FDA has granted accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic HNSCC that has progressed on or following platinum based-chemotherapy and immunotherapy. #hncsm #oncology Full story ➡️: onclive.com/view/fda-approve…
5
16
840
Brandon Rose, MD, MPH retweeted
✅ Changing target and payload ✅ Only changing payload 🫤 Only changing target
#ESMO26: Changing the cytotoxic payload may help to overcome resistance to antibody–drug conjugates (#ADCs). @RachelAbelman discusses studies investigating this strategy to improve patient responses in #BreastCancer. #InsightsbyESMO ➡️esmo.org/insights-by-esmo/al…
1
8
52
3,736
Brandon Rose, MD, MPH retweeted
⭐️Results from #HERIZON-GEA-01 presented at #ESMO26 Check out the full summary below 👇 #OncTwitter #MedTwitter #MedX #Oncology #GIOnc #gism #MedEd @myESMO
3
4
389
Brandon Rose, MD, MPH retweeted
Texas forever.
5,106
46,627
2,798
368,026
4,793,815
Brandon Rose, MD, MPH retweeted
Switching ADC payload works. Even while keeping the same target. We previously saw it in DB02. Then in TULIP. And now in ph1 trials of novel agents. In an abstract to be presented at #SABCS26, the HER2 ADC IKS014 (caxmotabart entudotin) showed an ORR of 50% (5/10) among patients with HER2+ MBC that had previously received T-DXd. biospace.com/press-releases/…
3
28
5
90
9,826
Brandon Rose, MD, MPH retweeted
6 years ago, I had the chance to publish a paper that would end up changing my academic life It was a review article exploring the surprising activity of certain ADCs in “HER2-low” breast cancer, a newly emerging entity whose relevance was still uncertain. We tried to connect the dots, asking if HER2-low was a subtype vs just a target, wondering whether this concept could one day translate into meaningful benefits for patients. 6 years later, that article has reached 1,000 citations. My career has gifted me more than I could ever have imagined. More importantly, what was once an intriguing scientific observation has become a clinical reality: countless patients with HER2-low breast cancer now live longer thanks to T-DXd. A reminder of how far science can take us in just a few years. Grateful to everyone who has been part of this journey! ascopubs.org/doi/10.1200/JCO…
7
19
3
250
16,613
Brandon Rose, MD, MPH retweeted
Thousands of clinical trials are looking for patients. Epic AI helps match trials with the right patients, giving them a new option for treatment. Since this spring, more than 60 organizations have started using it to automatically check study criteria against what’s already in the chart. Study teams can quickly see who may be a fit and invite them right in MyChart.
4
4
3
58
47,911
Brandon Rose, MD, MPH retweeted
⚡️ Concomitant publications demand extra effort from authors, reviewers and editorial team, but deliver what matters most: getting outstanding science out ASAP to advance cancer care. Glad to have handled 2 outstanding @ESMO_Open concomitant pubs by @kazuki_nozawa & @drsarahsam!
Concomitant publications at #ESMO26: new data moving swiftly from the podium to the peer-reviewed journals. @Annals_Oncology @ESMO_Open @NEJM @NatureMedicine @TheLancet @TheLancetOncol @Nature @JAMA_current
2
14
46
3,298
Brandon Rose, MD, MPH retweeted
Earlier this month, Heather McArthur, M.D., M.P.H., FASCO, and Carlos L. Arteaga, M.D., represented #UTSW and our Breast Cancer Program at the @BCRFcure 2026 Symposium & Awards Luncheon in New York, bringing together leaders in breast cancer research. @hmcarthur @CarlosArteagaMD
1
10
576